B
B E Souberbielle
Researcher at Pfizer
Publications - 28
Citations - 819
B E Souberbielle is an academic researcher from Pfizer. The author has contributed to research in topics: Immune system & Cytokine. The author has an hindex of 15, co-authored 26 publications receiving 790 citations. Previous affiliations of B E Souberbielle include University of St Andrews & St George's Hospital.
Papers
More filters
Journal ArticleDOI
Protein transduction: an alternative to genetic intervention?
TL;DR: This review describes the three most commonly used protein transduction vehicles; the antennapedia peptide, the herpes simplex virus VP22 protein and HIV TATprotein transduction domain.
Journal Article
Expression of a variant of cd28 on a subpopulation of human nk cells : implications for b7-mediated stimulation of nk cells
Joanna Galea-Lauri,David Darling,Shu Uin Gan,Leonid Krivochtchapov,M Kuiper,Joop Gaken,B E Souberbielle,Farzin Farzaneh +7 more
TL;DR: It is shown that human peripheral blood NK cells express the CD28 costimulatory receptor, with its detection totally dependent on the mAb used, and that B7.1 enhances the NK-mediated lysis of NK-sensitive but not ofNK-resistant tumor cells and that this increased lysis is dependent on CD28-B7 interactions as shown by the ability of Abs to block this lysis.
Journal ArticleDOI
Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury
Josef S. Ozer,Raj Chetty,Gerry Kenna,Joe Palandra,Yiqun Zhang,Anne Lanevschi,Nandan Koppiker,B E Souberbielle,Shashi K. Ramaiah +8 more
TL;DR: In this paper, the authors compare two types of drug-induced liver injury (DILI): intrinsic/predictable or an idiosyncratic type, and compare the two forms of DILI in their manifestation and diagnosis.
Journal ArticleDOI
The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).
Fidock,B E Souberbielle,Carl Laxton,Jaiessh Rawal,Oona Delpuech-Adams,TP Corey,P. Colman,Vivek Kumar,JB Cheng,K Wright,Srini S. Srinivasan,K Rana,Charles Craig,Nigel Horscroft,Manos Perros,Manos Perros,Mike Westby,Rob Webster,E van der Ryst +18 more
TL;DR: These doses of TLR7 stimulation results in a pharmacologic response at levels commensurate with predicted antiviral efficacy, but these doses are associated with SAEs, raising concerns about the therapeutic window of this class of compounds for the treatment of HCV infection.
Journal ArticleDOI
Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model
David Suhy,Shih-Chu Kao,Tin Mao,Laurence O. Whiteley,Hubert Denise,B E Souberbielle,Andrew D. Burdick,Kyle Hayes,J. Fraser Wright,Helen Lavender,Peter W. Roelvink,Alexander A. Kolykhalov,Kevin Brady,Sterghios Moschos,Bernd Hauck,Olga Zelenaia,Shangzhen Zhou,Curt Scribner,Katherine A. High,Katherine A. High,Sara H Renison,Romuald Corbau +21 more
TL;DR: A novel drug is described, intended as a “single-shot ” therapy, which expresses three short hairpin RNAs (shRNAs) that simultaneously target multiple conserved regions of the HCV genome as confirmed in vitro by knockdown of an HCV replicon system.